Avdoralimab (Anti-Complement C5aR1) is a fully human IgGκ monoclonal antibody targeting the complement C5a receptor 1 (C5aR1), that prevents its binding to C5a. Avdoralimab can be used for complement-driven inflammatory diseases and solid tumours research. MW: 145.5 KD.